The emergence of mephedrone as well as other artificial cathinones has presented problems for lawmakers and regulatory agencies tasked with managing the proliferation of latest psychoactive substances. The dynamic character of synthetic drug production, coupled with the power of chemists to modify molecular buildings to evade authorized limits, com